“Research is to see what everybody else has seen, and think what nobody has thought.”

-Dr. Albert Szent-Györgyi, MD, PhD de Nagyrápolt – 1937 winner of the Nobel Prize in Physiology or Medicine

Through the leadership and drive of Rebecca Lambert, NED Biosystems founder, and our expert team of scientists, NED’s approach is to find solutions that have yet to be imagined.

Our Mission and Principles

Our mission is to provide uncommon therapies so patients achieve and sustain “No Evidence of Disease.” Uncommon therapies are those that lack customary toxicity and side effects and allow patients to live life fully, and are those suitable for patients globally, including areas of the world plagued by health disparities.

We are driven by our guiding principles:

  • We work to the essential needs of patients and their families;
  • Integrity is woven into everything that we do;
  • Our therapies are scientifically grounded optimal solutions driven by continuous attention to new research findings;
  • We believe in the body’s innate ability to re-learn health;
  • We commit to challenge what “cannot be done”.

The Journey Begins

In 2001, NED founder Rebecca Lambert’s sister, Renée, was diagnosed with stage IV leiomyosarcoma (LMS), just 18 months after giving birth to a beautiful baby boy. LMS is a particularly deadly sarcoma, a rare type of cancer. Renée was given less than one year to live and “not a pretty one”. Rebecca became determined to develop a treatment that would permit her sister to spend more time with her son and that each day would be one with full quality of life.

Working with leading cancer researchers throughout the country, Rebecca assembled a research-based, multi-faceted treatment approach, analyzing the pathways that initiate and drive disease. Harvard’s Dr. Judah Folkman, a pioneer in “angiogenesis” (new blood vessel formation research) became her mentor. By taking a combination of well-reported oral agents, which successfully affect disease pathways, Renée lived for nine additional years. Maintaining her quality of life, Renée was also able to raise her son.

Shortly before Renée’s passing, Rebecca founded NED Biosystems, Inc. NED-170 CANCER, the company’s cancer treatment, has its roots in the early research conducted for her sister. This translational approach has been rapidly applied by a team of scientists to the development of NED’s treatment approach for COVID-19.

Rebecca Lambert

Founder and Executive Chairman

Rebecca Lambert has over 40 years of experience designing and executing strategies to solve complex issues confronting business, government, political, healthcare and financial entities. In recent years Ms. Lambert has focused on the development of NED’s lead candidate–NED-170 CANCER–as a treatment for multiple cancer indications.

Prior to founding NED, Ms. Lambert directed the raising of high net worth client funds to over $1B for Shaker Investments.  Previously, she founded two companies utilizing groundbreaking telecommunications technologies. Her prior Federal Government experience includes senior positions in the U.S. House, U.S. Senate, and the Reagan Administration. For five years, she served as President of Bellevue Hospital’s Bellevue Association Board.

Ms. Lambert has a BA in political science from Simmons College, and she completed Harvard Business School’s Advanced Management Program.

Her Full Bio

Leadership and Management

  • Geoffrey Ling, MD, PhD, Col. (Ret.)
    Geoffrey Ling, MD, PhD, Col. (Ret.)
    Office of the CEO, Scientific Advisory Board of Advisors, Board of Directors
  • Rebecca Lambert
    Rebecca Lambert
    Founder and Executive Chair, Office of the CEO
  • Brian Leyland Jones, BSc, MB BS, PhD, FRACP, FRCPC
    Brian Leyland Jones, BSc, MB BS, PhD, FRACP, FRCPC
    Scientific Advisory Board Chairman, Office of the CEO
  • Craig Eastwood, CPA
    Craig Eastwood, CPA
    Chief Financial Officer
  • Michael Mansour, MD, PhD
    Michael Mansour, MD, PhD
    Chief Medical Advisor - Infectious Disease
  • Lou Vaickus, MD, FACP
    Lou Vaickus, MD, FACP
    Chief Medical Advisor - Oncology
  • Sue Stewart, JD, LLM
    Sue Stewart, JD, LLM
    Senior Regulatory Advisor
  • Beth Silverstein, MS, RAC
    Beth Silverstein, MS, RAC
    Regulatory Advisor
  • Erminia Cafasso
    Erminia Cafasso
    Clinical Operations Advisor
  • William E. Gannon, Jr MD
    William E. Gannon, Jr MD
    Medical Director / Medical Monitor
  • Abdellah Sentissi, PhD
    Abdellah Sentissi, PhD
    Senior CMC and Product Development
  • Gary Elliot, RPh, PharmD, PhD
    Gary Elliot, RPh, PharmD, PhD
    CMC and Product Development
  • Brenda Jarrell, PhD, JD
    Brenda Jarrell, PhD, JD
    IP Counsel
  • Elinor Mullins
    Elinor Mullins
    Business Operations Director

Board of Directors

  • Geoffrey Ling, MD, PhD, Col. (Ret.)
    Geoffrey Ling, MD, PhD, Col. (Ret.)
    Office of the CEO, Scientific Advisory Board of Advisors, Board of Directors
  • Rebecca Lambert
    Rebecca Lambert
    Founder and Executive Chair, Office of the CEO
  • Randall Barko
    Randall Barko
    Board of Directors
  • Fiona Calnan FCCA, FRSA
    Fiona Calnan FCCA, FRSA
    Board of Directors
  • Mary Davis
    Mary Davis
    Board of Directors
  • Josh Kopelman – First Round Capital
    Josh Kopelman – First Round Capital
    Board Observer

Lead Investors

  • First Round Capital
    First Round Capital
    Series A Lead Investor
  • Benjamin H. Griswold, IV
    Benjamin H. Griswold, IV
    Series B Lead Investor

Scientific Advisory Board

  • Geoffrey Ling, MD, PhD, Col. (Ret.)
    Geoffrey Ling, MD, PhD, Col. (Ret.)
    Office of the CEO, Scientific Advisory Board of Advisors, Board of Directors
  • Brian Leyland Jones, BSc, MB BS, PhD, FRACP, FRCPC
    Brian Leyland Jones, BSc, MB BS, PhD, FRACP, FRCPC
    Scientific Advisory Board Chairman, Office of the CEO
  • Gail M. Fennell, MD
    Gail M. Fennell, MD
    Scientific Advisor
  • Edward Garmey, MD
    Edward Garmey, MD
    Scientific Advisor
  • Dudley R. Herschbach, PhD
    Dudley R. Herschbach, PhD
    Scientific Advisor
  • Judith E. Karp, MD
    Judith E. Karp, MD
    Scientific Advisor
  • Robert S. Kerbel, PhD
    Robert S. Kerbel, PhD
    Scientific Advisor
  • Razelle Kurzrock, MD
    Razelle Kurzrock, MD
    Scientific Advisor
  • Marsha A. Moses, PhD
    Marsha A. Moses, PhD
    Scientific Advisor

Strategic Advisory Council

  • Christine Davis
    Christine Davis
    Strategic Advisor
  • Louise Forlenza, CPA
    Louise Forlenza, CPA
    Strategic Advisor
  • Jean Hamilton
    Jean Hamilton
    Strategic Advisor
  • Gale Pollock, CRNA, FACHE, FAAN, Maj. Gen. (Ret)
    Gale Pollock, CRNA, FACHE, FAAN, Maj. Gen. (Ret)
    Strategic Advisor
  • Randy Slack
    Randy Slack
    Strategic Advisor
  • John Warden III, Col. (Ret)
    John Warden III, Col. (Ret)
    Strategic Advisor
  • Diane M. Whitty
    Diane M. Whitty
    Strategic Advisor
  • Jeffrey Yang
    Jeffrey Yang
    Strategic Advisor
  • Analisa L. Balares
    Analisa L. Balares
    Global Advisor

Advisors

  • Joy Horng
    Joy Horng
    Scientific Research Task Force
  • Susan Paulson, PhD
    Susan Paulson, PhD
    Clinical Pharmacology Advisor
  • Paul Woitach 
    Paul Woitach 
    CMC Advisor